Skip to main content

Table 1 Key characteristics of published pharmacokinetics studies of imipenem in critically ill patients undergoing CRRT [2, 9,10,11,12,13,14,15,16,17,18]

From: Imipenem dosing recommendations for patients undergoing continuous renal replacement therapy: systematic review and Monte Carlo simulations

References CRRT mode SC or SA Vd (L/kg) CLNR (ml/min) CLCRRT (ml/min) Pre-specified PD target Dose recommendation
Keller et al. [20] CAVH 1.16 0.29 108.5 ± 29.6 7.0 ± 3.4 NS NS
Przechera et al. [16] CAVH 1.13 ± 0.12 0.47 ± 0.16 6.49 NS NS
Vos et al. [18] CAVH
CAVHD
SC: 1.05 ± 0.19 9 ± 3 (CVVH)
16 ± 7 (Qd 1 L/h)
30 ± 7 (Qd 3 L/h)
NS NS
Mueller et al. [2] CVVH 0.8 0.33 ± 0.09 95 ± 13.8 13.3 NS NS
Hashimoto et al. [24] CVVHD 0.38 ± 0.13 70.62 ± 14.6 18.74 ± 1.2 NS NS
Fish et al. [23] CVVH
CVVHDF
1.21 ± 0.11
(CVVH),
1.28 ± 0.17
(CVVHDF)
0.36 ± 0.1
(CVVH),
0.37 ± 0.13
(CVVHDF)
109 ± 24
(CVVH),
120 ± 32
(CVVHDF)
36 ± 13
(CVVH),
57 ± 28
(CVVHDF)
Yes Yes
Afshartous et al. [21] CVVHD 0.32 32.4 ± 9.8* Yes NS
Boucher et al. [22] CVVH 1.01 ± 0.12 0.39 ± 0.27 191.5 54.5 No NS
Wen et al. [19] CVVHDF
CVVH
0.37 ± 0.19 (CVVHDF)
1.11
(CVVH)
1.9 mL/min/kg (CVVHDF)
2.8 mL/min/kg (CVVH)
Yes NS
Breilh et al. [26] CVVH 0.52–0.80 0.33 236.59 32.62 Yes NS
  1. NS, data not stated
  2. *Carbapenem CRRT clearance